Drugs for the treatment of overactive bladder syndrome: present and future (A Review)

被引：0

作者：

Shvarts, G. Ya. ^{[1
]}

Shvarts, P. G. ^{[2
]}

Plotnikov, A. N. ^{[2
]}

Savvin, D. Yu. ^{[2
]}

机构：

[1] Sechenov First Moscow State Med Univ, Moscow 119991, Russia

[2] Russian Acad Med Sci, Res Ctr Neurol, Moscow 125367, Russia

来源：

PHARMACEUTICAL CHEMISTRY JOURNAL | 2013年 / 46卷 / 12期

关键词：

overactive bladder syndrome; anticholinergic drugs; LOWER URINARY-TRACT; DYSFUNCTION PATHOPHYSIOLOGY; DETRUSOR OVERACTIVITY; MIRABEGRON; FOREFRONT; SYMPTOMS; EFFICACY;

D O I：

10.1007/s11094-013-0873-x

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Published data concerning drugs currently used for the treatment of overactive bladder (OAB) syndrome were reviewed. Modern notions about the physiology and pathophysiology of micturition were considered and data on the pharmacological properties, tolerance, and therapeutic efficiency of anticholinergic drugs (antimuscarinic agents), the first-line drugs for treating OAB, were presented. Data on drugs with a different mechanism of action that are currently used to treat OAB were reviewed. Information on the principal directions of new drug development, in particular, beta 3-adrenoreceptor agonists, compounds affecting KCNQ/Kv7-channels, vitamin D receptors, etc., was summarized.

引用

页码：699 / 706

页数：8

共 28 条

[1] Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2] Muscarinic receptor antagonists for overactive bladder
Abrams, Paul
Andersson, Karl-Erik
[J]. BJU INTERNATIONAL, 2007, 100 (05) : 987 - 1006
[3] Drugs and future candidates
Andersson, Karl-Erik
[J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2011, 5 (03): : S131 - S133
[4] Prospective pharmacologic therapies for the overactive bladder
Andersson, Karl-Erik
[J]. THERAPEUTIC ADVANCES IN UROLOGY, 2009, 1 (02) : 71 - 83
[5] Detrusor Myocyte Activity and Afferent Signaling
Andersson, Karl-Erik
[J]. NEUROUROLOGY AND URODYNAMICS, 2010, 29 (01) : 97 - 106
[6] CNS involvement in overactive bladder - Pathophysiology and opportunities for pharmacological intervention
Andersson, KE
Pehrson, R
[J]. DRUGS, 2003, 63 (23) : 2595 - 2611
[7] The medical treatment of overactive bladder, including current and future treatments
Athanasopoulos, Anastasios
Cruz, Francisco
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (07) : 1041 - 1055
[8] DOSE-RANGING STUDY OF ONCE-DAILY MIRABEGRON (YM178), A NOVEL SELECTIVE β3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER (OAB)
Chapple, C.
Wyndaele, J. J.
Van Kerrebroeck, P.
Radziszewski, P.
Dvorak, V.
Boerrigter, P.
[J]. EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 249 - 249
[9] Overactive bladder treatments in early phase clinical trials
Colli, Enrico
Digesu, Giuseppe Alessandro
Olivieri, Lorenza
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (07) : 999 - 1007
[10] Dobrek L, 2011, ACTA POL PHARM, V68, P807

← 1 2 3 →